{
    "clinical_study": {
        "@rank": "45044", 
        "acronym": "AICE", 
        "arm_group": [
            {
                "arm_group_label": "Regimen B, PEip and TCiv therapy", 
                "arm_group_type": "Experimental", 
                "description": "Weekly IP cisplatin plus etoposide followed by IV paclitaxel plus carboplatin or docetaxel plus carboplatin"
            }, 
            {
                "arm_group_label": "Regimen A: Standard TCiv therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "IV paclitaxel plus carboplatin or docetaxel plus carboplatin"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the role of an additional intraperitoneal\n      chemotherapy with cisplatin and etoposide in bulky advanced epithelial ovarian cancer."
        }, 
        "brief_title": "First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Bulky Stage IIIC and IV Epithelial Ovarian Cancer,", 
            "Fallopian Tube Cancer,", 
            "Primary Peritoneal Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Ovarian Neoplasms", 
                "Fallopian Tube Neoplasms", 
                "Neoplasms, Glandular and Epithelial"
            ]
        }, 
        "detailed_description": {
            "textblock": "This exploratory trial is to compare the efficacy of sequential chemotherapy,\n      intraperitoneal chemotherapy followed by intravenous chemotherapy, versus intravenous\n      chemotherapy alone in the first-line therapy for ovarian cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u226518 years to \u2264 75 years.\n\n          -  Epithelial ovarian cancer with pathology confirmed stage IIIc or IV, expect for lymph\n             node metastasis alone\n\n          -  Optimal cytoreductive surgery, including hysterectomy, bilateral\n             salpinges-oophorectomy, omentectomy, and resection of all metastatic lesions, with a\n             residual disease no more than 1cm\n\n          -  Available to receive intraperitoneal chemotherapy 5-10 days postoperative, or no more\n             than postoperative 14 days for those with bowel resection.\n\n          -  ECOG performance 0-2.\n\n          -  No more than 3 cycles of chemotherapy prior to surgery.\n\n          -  Laboratory testing within 7 days of registration: hematopoietic: absolute neutrophil\n             count greater than 1,500/mm3; Platelet count greater than 100,000/mm3. Hepatic:\n             bilirubin less than 1.25 times upper limit of normal (ULN); Bilirubin < 2.0, SGPT\n             less than 2 times ULN. Renal: creatinine less than 1.6 mg/dL, OR creatinine clearance\n             greater than 40 mL/min.\n\n          -  Comply with intraperitoneal chemotherapy and follow-up.\n\n          -  Written informed consent.\n\n        Exclusion Criteria:\n\n          -  Low-malignant potential ovarian tumor.\n\n          -  Laboratory testing insufficiency. Hemoglobin < 10 g/dL. Renal insufficiency with\n             serum creatinine > 1.6.\n\n          -  Bone marrow dysfunction: absolute neutrophil count less than 1,500/mm3; Platelet\n             count less than 80,000/mm3.\n\n          -  Active infection.\n\n          -  Clinically significant gastrointestinal abnormalities.\n\n          -  Active coronary artery disease, cerebrovascular disease, restrictive or obstructive\n             pulmonary disease, or congestive heart failure.\n\n          -  Other condition that could interfere with provision of informed consent, compliance\n             to study procedures, or follow-up.\n\n          -  Prior invasive malignancies within the last 5 years showing activity of disease."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01669226", 
            "org_study_id": "V01-2009-03"
        }, 
        "intervention": [
            {
                "arm_group_label": "Regimen B, PEip and TCiv therapy", 
                "description": "IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5", 
                "intervention_name": "PEip (weekly) and TCiv", 
                "intervention_type": "Drug", 
                "other_name": [
                    "platinum", 
                    "VP 16", 
                    "taxane"
                ]
            }, 
            {
                "arm_group_label": "Regimen A: Standard TCiv therapy", 
                "description": "IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5", 
                "intervention_name": "TCiv", 
                "intervention_type": "Drug", 
                "other_name": [
                    "taxane", 
                    "platinum"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Etoposide phosphate", 
                "Cisplatin", 
                "Etoposide", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ovarian Cancer", 
            "intraperitoneal chemotherapy"
        ], 
        "lastchanged_date": "January 2, 2013", 
        "location": [
            {
                "contact": {
                    "email": "z_m_7_0@yahoo.com.cn", 
                    "last_name": "Mi Zhang, MD", 
                    "phone": "+8613584887057"
                }, 
                "facility": {
                    "address": {
                        "city": "Suzhou", 
                        "country": "China", 
                        "state": "Jiangsu"
                    }, 
                    "name": "Suzhou Municipal Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ssli2004@163.com", 
                    "last_name": "Shan Su, MD", 
                    "phone": "+8613861768827"
                }, 
                "facility": {
                    "address": {
                        "city": "Wuxi", 
                        "country": "China", 
                        "state": "Jiangsu"
                    }, 
                    "name": "Wuxi Cancer Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "xipengwang@hotmail.com", 
                    "last_name": "Xipeng Wang, MD,PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai"
                    }, 
                    "name": "Shanghai Frist Maternity and Infant Hospital Affiliated to Tongji University"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "lilyqiulh@126.com", 
                    "last_name": "Lihua Qiu, MD,PhD", 
                    "phone": "+862158752345"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai"
                    }, 
                    "name": "Ren Ji Hospital Affiliated to Shanghai JiaoTong University School of Medicine"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "yutingluan@163.com", 
                    "last_name": "Yuting Luan, RN", 
                    "phone": "+862164175590"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200032"
                    }, 
                    "name": "Fudan University Cancer Hospital"
                }, 
                "investigator": {
                    "last_name": "Rongyu Zang, MD,PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II,Randomized Study of an Addition Intraperitoneal Cisplatin and Etoposide to Standard First-line Therapy in Stage IIIC and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)", 
        "overall_contact": {
            "email": "fudanGOG@gmail.com", 
            "last_name": "Jie Tang, MD,PhD", 
            "phone": "+862164175590"
        }, 
        "overall_contact_backup": {
            "email": "yutingluan@163.com", 
            "last_name": "Yuting Luan, RN", 
            "phone": "+862164175590"
        }, 
        "overall_official": {
            "affiliation": "Shanghai Gynecologic Oncology Group", 
            "last_name": "Rongyu Zang, MD,PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "12-month disease non-progression rate", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01669226"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "up to 120 months"
            }, 
            {
                "measure": "Completion rate of intraperitoneal chemotherapy.", 
                "safety_issue": "Yes", 
                "time_frame": "up to 6 months"
            }, 
            {
                "measure": "Quality of life assessments", 
                "safety_issue": "No", 
                "time_frame": "baseline; 4th week of intraperitoneal,chemotherapy, 6th cycle of intravenous chemotherpy, 3, 6, and 12 months after first-line chemotherapy."
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "up to 120 months"
            }, 
            {
                "measure": "adverse effects", 
                "safety_issue": "Yes", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 5 weeks"
            }
        ], 
        "source": "Shanghai Gynecologic Oncology Group", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Fudan University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shanghai JiaoTong University School of Medicine", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Soochow University (Jiangsu)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Tongji University (Shanghai)", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Shanghai Gynecologic Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}